PubMed:29955381 JSONTXT

{"project":"Zierdiyeerkenaili_800_3","denotations":[{"id":"T1","span":{"begin":508,"end":510},"obj":"DP"},{"id":"T10","span":{"begin":435,"end":445},"obj":"CI"},{"id":"T11","span":{"begin":558,"end":568},"obj":"CI"},{"id":"T12","span":{"begin":755,"end":765},"obj":"CI"},{"id":"T13","span":{"begin":982,"end":992},"obj":"CI"},{"id":"T14","span":{"begin":1045,"end":1055},"obj":"CI"},{"id":"T15","span":{"begin":1314,"end":1324},"obj":"CI"},{"id":"T16","span":{"begin":1356,"end":1366},"obj":"CI"},{"id":"T17","span":{"begin":2055,"end":2065},"obj":"CI"},{"id":"T18","span":{"begin":542,"end":554},"obj":"CI"},{"id":"T19","span":{"begin":105,"end":117},"obj":"CI"},{"id":"T2","span":{"begin":315,"end":317},"obj":"DP"},{"id":"T20","span":{"begin":366,"end":378},"obj":"CI"},{"id":"T21","span":{"begin":446,"end":458},"obj":"CI"},{"id":"T22","span":{"begin":570,"end":582},"obj":"CI"},{"id":"T23","span":{"begin":830,"end":842},"obj":"CI"},{"id":"T24","span":{"begin":1071,"end":1083},"obj":"CI"},{"id":"T25","span":{"begin":1373,"end":1385},"obj":"CI"},{"id":"T26","span":{"begin":1420,"end":1432},"obj":"CI"},{"id":"T27","span":{"begin":1434,"end":1446},"obj":"CI"},{"id":"T28","span":{"begin":1501,"end":1513},"obj":"CI"},{"id":"T29","span":{"begin":1550,"end":1562},"obj":"CI"},{"id":"T3","span":{"begin":293,"end":313},"obj":"DP"},{"id":"T30","span":{"begin":1822,"end":1834},"obj":"CI"},{"id":"T31","span":{"begin":1874,"end":1884},"obj":"CI"},{"id":"T32","span":{"begin":2066,"end":2086},"obj":"CI"},{"id":"T4","span":{"begin":135,"end":155},"obj":"DP"},{"id":"T5","span":{"begin":530,"end":540},"obj":"CI"},{"id":"T6","span":{"begin":17,"end":27},"obj":"CI"},{"id":"T7","span":{"begin":89,"end":99},"obj":"CI"},{"id":"T8","span":{"begin":329,"end":339},"obj":"CI"},{"id":"T9","span":{"begin":355,"end":365},"obj":"CI"},{"id":"T34","span":{"begin":469,"end":481},"obj":"CI"},{"id":"T35","span":{"begin":993,"end":1009},"obj":"CI"}],"text":"Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis.\nOBJECTIVE: To evaluate long-term clinical, functional and radiographic outcomes in an open-label extension (OLE) study in patients with rheumatoid arthritis (RA) receiving adalimumab monotherapy or adalimumab+methotrexate following attainment of low disease activity (LDA) with adalimumab+methotrexate.\nMETHODS: Methotrexate-naive patients with early RA were randomised to adalimumab, methotrexate or adalimumab +methotrexate in a double-blind, 2-year study. Patients who completed the study and achieved LDA (28-joint Disease Activity Score using C reactive protein (DAS28(CRP)\u003c3.2) could receive adalimumab monotherapy for up to 8 additional years in the OLE; open-label methotrexate could be added per investigator's discretion. This post hoc analysis included data up to OLE year 3 (study year 5) from patients receiving adalimumab+methotrexate who achieved LDA at year 2 followed by adalimumab monotherapy or methotrexate reinitiation. Normal physical function was defined as Disability Index of the Health Assessment Questionnaire \u003c0.5 and radiographic non-progression as change in modified total Sharp score ≤0.5.\nRESULTS: Of 140 patients initiating adalimumab monotherapy, 84 (60%) received adalimumab only (methotrexate non-use) and 56 (40%) reinitiated methotrexate (methotrexate use) during OLE treatment. Median (IQR) time to first methotrexate use was 5.1 (0.1-31.4) weeks. Among methotrexate users, 61% retained LDA, 48% achieved DAS28(CRP) \u003c2.6, 45% had normal physical function and 46% had no radiographic progression at year 5; for non-users, 63%, 50%, 58% and 50%, respectively, achieved these milestones. Adverse event rates were similar between methotrexate non-use and use patients.\nCONCLUSIONS: Adalimumab monotherapy effectively maintained good clinical, functional and radiographic outcomes for up to 3 additional years in ≥50% of patients who attained LDA after 2 years of adalimumab+methotrexate therapy.\nTRIAL REGISTRATION NUMBER: NCT00195663; Post-results."}

{"project":"yaoziqian_800_3","denotations":[{"id":"T1","span":{"begin":135,"end":155},"obj":"DP"},{"id":"T10","span":{"begin":469,"end":481},"obj":"CI"},{"id":"T11","span":{"begin":508,"end":510},"obj":"DP"},{"id":"T12","span":{"begin":530,"end":540},"obj":"CI"},{"id":"T13","span":{"begin":542,"end":554},"obj":"CI"},{"id":"T14","span":{"begin":558,"end":568},"obj":"CI"},{"id":"T15","span":{"begin":570,"end":582},"obj":"CI"},{"id":"T16","span":{"begin":755,"end":765},"obj":"CI"},{"id":"T17","span":{"begin":982,"end":992},"obj":"CI"},{"id":"T19","span":{"begin":1045,"end":1055},"obj":"CI"},{"id":"T2","span":{"begin":89,"end":99},"obj":"CI"},{"id":"T20","span":{"begin":1071,"end":1083},"obj":"CI"},{"id":"T21","span":{"begin":17,"end":27},"obj":"CI"},{"id":"T23","span":{"begin":1314,"end":1324},"obj":"CI"},{"id":"T24","span":{"begin":1356,"end":1366},"obj":"CI"},{"id":"T25","span":{"begin":1420,"end":1432},"obj":"CI"},{"id":"T26","span":{"begin":1434,"end":1446},"obj":"CI"},{"id":"T27","span":{"begin":1373,"end":1385},"obj":"CI"},{"id":"T28","span":{"begin":1501,"end":1513},"obj":"CI"},{"id":"T29","span":{"begin":1550,"end":1562},"obj":"CI"},{"id":"T3","span":{"begin":105,"end":117},"obj":"CI"},{"id":"T30","span":{"begin":1822,"end":1834},"obj":"CI"},{"id":"T31","span":{"begin":1874,"end":1884},"obj":"CI"},{"id":"T32","span":{"begin":2055,"end":2065},"obj":"CI"},{"id":"T33","span":{"begin":2066,"end":2086},"obj":"CI"},{"id":"T4","span":{"begin":293,"end":313},"obj":"DP"},{"id":"T5","span":{"begin":329,"end":339},"obj":"CI"},{"id":"T6","span":{"begin":355,"end":365},"obj":"CI"},{"id":"T7","span":{"begin":366,"end":378},"obj":"CI"},{"id":"T8","span":{"begin":435,"end":445},"obj":"CI"},{"id":"T9","span":{"begin":446,"end":458},"obj":"CI"},{"id":"T34","span":{"begin":315,"end":317},"obj":"DP"},{"id":"T35","span":{"begin":993,"end":1009},"obj":"CI"},{"id":"T36","span":{"begin":830,"end":842},"obj":"CI"}],"text":"Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis.\nOBJECTIVE: To evaluate long-term clinical, functional and radiographic outcomes in an open-label extension (OLE) study in patients with rheumatoid arthritis (RA) receiving adalimumab monotherapy or adalimumab+methotrexate following attainment of low disease activity (LDA) with adalimumab+methotrexate.\nMETHODS: Methotrexate-naive patients with early RA were randomised to adalimumab, methotrexate or adalimumab +methotrexate in a double-blind, 2-year study. Patients who completed the study and achieved LDA (28-joint Disease Activity Score using C reactive protein (DAS28(CRP)\u003c3.2) could receive adalimumab monotherapy for up to 8 additional years in the OLE; open-label methotrexate could be added per investigator's discretion. This post hoc analysis included data up to OLE year 3 (study year 5) from patients receiving adalimumab+methotrexate who achieved LDA at year 2 followed by adalimumab monotherapy or methotrexate reinitiation. Normal physical function was defined as Disability Index of the Health Assessment Questionnaire \u003c0.5 and radiographic non-progression as change in modified total Sharp score ≤0.5.\nRESULTS: Of 140 patients initiating adalimumab monotherapy, 84 (60%) received adalimumab only (methotrexate non-use) and 56 (40%) reinitiated methotrexate (methotrexate use) during OLE treatment. Median (IQR) time to first methotrexate use was 5.1 (0.1-31.4) weeks. Among methotrexate users, 61% retained LDA, 48% achieved DAS28(CRP) \u003c2.6, 45% had normal physical function and 46% had no radiographic progression at year 5; for non-users, 63%, 50%, 58% and 50%, respectively, achieved these milestones. Adverse event rates were similar between methotrexate non-use and use patients.\nCONCLUSIONS: Adalimumab monotherapy effectively maintained good clinical, functional and radiographic outcomes for up to 3 additional years in ≥50% of patients who attained LDA after 2 years of adalimumab+methotrexate therapy.\nTRIAL REGISTRATION NUMBER: NCT00195663; Post-results."}